Ten post jest także dostępny w języku: polski
The Neuca Group press centre has reported that it has developed a coronavirus test to detect the presence of the Sars-CoV-2 pathogen even at a very early stage of infection. The test will be introduced to the Polish market by SensDx, a company in which Neuca holds a part of shares.
Speed and effectiveness in diagnosing coronavirus
Diagnostic studies during the digestive coronavirus pandemic form the basis for combating the spread of COVID-19 in society. Currently, the most common method of detecting these infections is the RT-PCR genetic test, the result of which has to wait 1-3 days.
SensDx S.A. has developed a rapid Sars-CoV-2 test that detects the presence of the pathogen even at a very early stage of infection, with sensitivity and specificity at the level of RT-PCR (genetic) test. A reliable result can be read after 6 minutes. Jagiellonian University was involved in the development of Sars-CoV-2 detection. According to Neuca, the team of Prof. Krzysztof Pyrc from the Malopolska Center of Biotechnology defined the specific and most conservative protein of Sars-CoV-2 virus for further detection using SensDx technology. As part of the construction of the Sars-CoV-2 test, support in the field of biotechnology was provided by the Institute of Biotechnology and Molecular Medicine.
Not only the Sars-CoV-2 test
The SensDx test is designed for use outside the laboratory. It is designed to enable rapid patient diagnosis at airports, emergency services, clinics, pharmacies and checkpoints, among others.
The test enables the diagnosis of coronavirus and influenza A/B virus in one swab. This may prove to be very important if the increase in COVID-19 incidence coincides with the next influenza season in the autumn. The SensDx test detects the presence of active virus protein and does not show a false positive result if residual RNA of the inactive virus is present. This solution is to be available in a few weeks’ time at 200 clinics (their addresses will be provided on the SensDx website). Currently, the Sars-CoV-2 test is valued at about PLN 200-250. However, the target cost of the test is to be below PLN 100.
Photo: Neuca Press Center, Mobi reader with a one-time test.